Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PI | Common Stock | Options Exercise | $112K | +5K | +1.75% | $22.40 | 291K | Jun 10, 2024 | Direct | |
transaction | PI | Common Stock | Sale | -$393K | -2.67K | -0.92% | $147.36 | 289K | Jun 10, 2024 | Direct | F1, F2 |
transaction | PI | Common Stock | Sale | -$329K | -2.22K | -0.77% | $148.18 | 286K | Jun 10, 2024 | Direct | F1, F3 |
transaction | PI | Common Stock | Sale | -$16.7K | -112 | -0.04% | $149.36 | 286K | Jun 10, 2024 | Direct | F1, F4 |
transaction | PI | Common Stock | Options Exercise | $112K | +5K | +1.75% | $22.40 | 291K | Jun 11, 2024 | Direct | |
transaction | PI | Common Stock | Sale | -$309K | -2.12K | -0.73% | $145.89 | 289K | Jun 11, 2024 | Direct | F1, F5 |
transaction | PI | Common Stock | Sale | -$423K | -2.88K | -1% | $146.94 | 286K | Jun 11, 2024 | Direct | F1, F6 |
transaction | PI | Common Stock | Sale | -$590 | -4 | 0% | $147.45 | 286K | Jun 11, 2024 | Direct | F1 |
holding | PI | Common Stock | 552K | Jun 10, 2024 | by DFT L.L.C. |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PI | Stock Option (right to buy) | Options Exercise | $0 | -5K | -4.15% | $0.00 | 116K | Jun 10, 2024 | Common Stock | 5K | $22.40 | Direct | F7 |
transaction | PI | Stock Option (right to buy) | Options Exercise | $0 | -5K | -4.33% | $0.00 | 111K | Jun 11, 2024 | Common Stock | 5K | $22.40 | Direct | F7 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Id | Content |
---|---|
F1 | The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on February 28, 2024. |
F2 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $146.915 to $147.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
F3 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $147.925 to $148.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
F4 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $149.27 to $149.41 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
F5 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $145.29 to $146.2625, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
F6 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $146.33 to $147.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
F7 | The option became fully vested on June 11, 2022. |